Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(35 sites)
United States
University of California Los Angeles, Los Angeles, California University of California, San Francisco (Ucsf) School of Medicine, San Francisco, California Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute, Lake Mary, Florida Community Health Network, Indianapolis, Indiana Dana Farber Cancer Institue, Boston, Massachusetts Duke University School of Medicine, Durham, North Carolina Taylor Cancer Research Center, Maumee, Ohio SCRI Oncology Partners, Nashville, Tennessee NEXT Oncology, Austin, Texas Australia
Scientia Clinical Research, Randwick, New South Wales The Alfred, Prahran, Victoria Townsville University Hospital, Douglas Royal Hobart Hospital, Hobart Denmark
University Hospital Rigshospitalet, Copenhagen Odense Universitets Hospital, Odense France
Institut Bergonié, Bordeaux Centre Georges-François Leclerc, Dijon Hôpital de la Timone (Marseille), Marseille Institut Gustave Roussy, Paris Germany
Charite Universitatsmedizin, Berlin Universitätsklinikum Düsseldorf, Düsseldorf Med Fakultaet Heidelberg, Heidelberg Universitätsklinikum Ulm, Ulm Italy
Istituto Europeo Di Oncologia, Milan A.O.U. Seconda Università Degli Studi Di Napoli, Naples Ist. Nazionale Tumori Irccs Fondazione G Pascale, Naples Instituto Clinico Humanitas Irccs, Rozzano Policlinico G.B. Rossi A.O.U.I. Di Verona, Verona Japan
Aichi Cancer Center, Aichi National Hospital Organization Shikoku Cancer Center, Ehime The Cancer Institute Hospital of JFCR, Tokyo Spain
Next Oncology-Hospital Quironsalud Barcelona, Barcelona Hospital Vall D'Hebron, Barcelona Hospital Universitario Fundación Jiménez Díaz, Madrid Start Madrid Group - Hm Ciocc, Madrid